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Abstract
IMPORTANCE—Testing for and treating latent tuberculosis infection (LTBI) is among the main 
strategies to achieve TB elimination in the United States. The best approach to testing among non-
US born residents, particularly those with comorbid conditions, is uncertain.
OBJECTIVE—To estimate health outcomes, costs, and cost-effectiveness of LTBI testing and 
treatment among non-US born residents with and without medical comorbidities.
DESIGN, SETTING, AND PARTICIPANTS—Decision analytic tree and Markov cohort 
simulation model among non-US born residents with no comorbidities, with diabetes, with HIV 
infection, or with end-stage renal disease (ESRD) using a health care sector perspective with 3% 
annual discounting. Strategies compared included no testing, tuberculin skin test (TST), interferon 
gamma release assay (IGRA), confirm positive (initial TST, IGRA only for TST-positive results; 
both tests positive indicates LTBI), and confirm negative (initial IGRA, then TST for IGRA-
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negative; any test positive indicates LTBI). All strategies were coupled to treatment with 3 months 
of self-administered rifapentine and isoniazid.
MAIN OUTCOMES AND MEASURES—Number needed to test and treat to prevent 1 case of 
TB reactivation, discounted quality-adjusted life-years (QALYs), discounted lifetime medical 
costs, and incremental cost-effectiveness ratios (ICERs).
RESULTS—Improving health outcomes increased costs, with choice of test dependent on 
willingness to pay. Strategies ranked by ascending costs and benefits: no testing, confirm positive, 
TST, IGRA, and confirm negative. The ICERs varied by non–US born patient risk group: patients 
with no comorbidities, IGRA was likely cost-effective at $83 000/QALY; patients with diabetes, 
both confirm positive ($53 000/QALY) and IGRA ($120 000/QALY) were likely cost-effective; 
patients with HIV, confirm negative was clearly preferred ($63 000/QALY); and patients with 
ESRD, no testing was cost-effective. Increased LTBI prevalence and reduced return for TST 
reading improved IGRA’s relative performance. In 10 000 probabilistic simulations among non-
US born patients with no comorbidities, with diabetes, and with HIV, some form of testing was 
virtually always cost-effective. These simulations highlight the uncertainty of test choice for non-
US born patients with no comorbidities and non-US born patients with diabetes, but strategies 
including IGRA were preferred in over 60% of simulations for all non–US born populations 
except those with ESRD.
CONCLUSIONS AND RELEVANCE—Testing for and treating LTBI among non-US born 
residents with and without selected comorbidities is likely cost-effective except among those with 
ESRD in whom competing risks of death limit benefits. Strategies including IGRA fell below a 
$100 000/QALY willingness-to-pay threshold for non-US born patients with no comorbidities, 
patients with diabetes, and patients with HIV.
Most cases of tuberculosis (TB) in the United States occur among non-US born residents.1 
Previous studies suggest that testing and treatment with isoniazid for latent TB infection 
(LTBI) among non–US born persons is cost-effective.2 Common comorbidities among non-
US born persons, such as diabetes, end-stage renal disease (ESRD), and HIV infection, 
increase the risk of TB reactivation while carrying competing risks of death that may limit 
the health benefits of testing and treatment.3 Since the publication of previous cost-
effectiveness analyses, the treatment regimen of rifapentine and isoniazid administered 
weekly for 3 months by directly observed therapy and self-administration was found to be 
safe, effective, and cost-effective among LTBI patients in the United States.4–7 The 
economic value of LTBI testing and 3 months of treatment with self-administered 
rifapentine and isoniazid in non–US born patients with medical comorbidities is not clear.3,8
There are multiple LTBI testing strategies, including tuberculin skin tests (TSTs), interferon 
gamma release assays (IGRAs), and combinations of the 2 measures. Centers for Disease 
Control and Prevention guidance for testing and treatment of LTBI suggests that, in some 
patients, using 2 tests together to maximize the sensitivity of the LTBI testing algorithm is 
appropriate, but the long-term benefits and value of such combined testing approaches are 
not certain.9–13
We used a decision-analytic Markov model to estimate clinical outcomes, costs, and cost-
effectiveness of testing for and treatment of LTBI among non–US born persons in the United 
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States. We considered testing with TST, IGRA, or in combination, and included 3 months of 
LTBI treatment with self-administered rifapentine and isoniazid. The results are intended to 
inform health care professionals seeking guidance on LTBI testing and policymakers seeking 
to recommend cost-effective interventions.
Methods
Overview
We developed a simulation model to investigate LTBI testing and treatment in 4 non-US 
born populations: with no comorbidities, with diabetes, with HIV, and with ESRD. 
Outcomes from the model include the number needed to test and treat (NNT) to prevent 1 
case of reactivation TB, life expectancy, discounted quality-adjusted life expectancy, 
discounted lifetime medical costs, and incremental cost-effectiveness ratios (ICERs). All 
cost outcomes are reported in 2015 US dollars. The study was approved by Harvard 
University Institutional Review Board.
Model Structure
The model includes 2 components: a decision tree capturing outcomes relating to testing and 
a Markov model simulating the lifetime progression of a cohort of people. We developed the 
model using TreeAge software, version 2015 (TreeAge Corp).
Decision Tree—We modeled 5 testing strategies: no testing, TST, IGRA, confirm positive 
(patients with a positive TST given IGRA, with both positive resulting in LTBI diagnosis), 
and confirm negative (patients with a negative IGRA given TST, with either positive 
resulting in LTBI diagnosis). The branches of the decision tree capture the prevalence of 
LTBI, the probability of testing positive, and the probability of initiating treatment. Patients 
may be lost to follow-up before TST reading. At the ends of each branch in the decision tree, 
patients are separated into 4 groups to be “handed off” to the Markov model: LTBI with 
treatment, LTBI without treatment, no LTBI with treatment, and no LTBI without treatment.
Markov Model—The Markov model simulates long-term outcomes related to the natural 
history of LTBI, including progression to active TB (reactivation) and mortality from TB or 
other causes. The rate of TB reactivation decreases as the cohort ages. Across risk groups, a 
proportion with active TB develops severe TB disease, characterized by higher medical 
costs, hospitalization, and increased risk of death. Outpatient treatment of TB is associated 
with 6 months of increased mortality, decreased quality of life, and additional costs 
associated with treatment, while severe TB lasts for 9 months. Patients who survive TB are 
cured with no further risk of TB reactivation.
We modeled LTBI therapy as 3 months of self-administered rifapentine and isoniazid4,14–16 
and assumed that LTBI treatment without toxic effects causes no change in quality of life. 
Completed LTBI therapy reduces the monthly probability of TB reactivation. Patients can 
withdraw from therapy due to toxic effects (adding 1 month of additional cost and quality-
of-life decrement and possibility of death) or nonadherence. We assumed no partial 
protection for those who withdraw.
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For each case of reactivation TB, we modeled additional TB cases due to transmission. Each 
secondary case results in additional cost and decreased life expectancy, estimated as the 
difference in outcomes between a healthy 35-year-old and a 35-year-old individual with 
active TB. We did not consider transmission beyond the first generation.
We modeled age- and sex-specific mortality from causes other than TB; non-US born 
patients with no comorbidities have the same competing risks of death as the US general 
population. We modeled elevated mortality and increased medical costs among the non-US 
born patients with diabetes, with HIV, and with ESRD cohorts.17–19 Despite a high 
prevalence of diabetes in the ESRD population, our model does not distinguish between 
those cohorts. The additional cost and risk of death from ESRD is greater than any other 
differences between these subpopulations.
Model Data
We conducted a meta-analysis to estimate the diagnostic performance of TST and IGRA 
(eAppendix in the Supplement).20 Using a Bayesian latent class model, we predicted test 
characteristics for each risk group, which are reported in Table 1.
We selected model parameters from medical literature (Table 1). Miramontes et al40 reported 
LTBI prevalence in non-US born individuals of 15.9% using National Health and Nutrition 
Examination Survey data. We used an 18% failure of non-US born persons to return for TST 
reading reported by Desale et al.25
We applied a rate of TB reactivation without LTBI treatment in the general non-US born 
population of 104 cases per 100 000 person-years at risk.22,41 For each decade after 
simulation start, we assumed a 10% reduction in the base reactivation rate due to self-cure.42 
Monthly risk of reactivation was higher in populations with comorbidities. The non-US born 
patients with diabetes and non-US born patients with ESRD had 1.8 times the monthly rate 
of reactivation of non-US born patients with no comorbidities,29 while the baseline 
reactivation rate for non-US born patients with HIV was 3.5 times higher.28 Completed 
LTBI treatment confers a 90% reduction in the modeled rate of reactivation.4
Medicare-allowable fees were applied as cost estimates for IGRA and TST ($84.35 vs 
$7.87).32 Therapy costs accrued monthly; patients who failed to complete the course did not 
incur the full cost of treatment ($582).32,34,43 Treatment-related toxic effects resulted in an 
additional $323 in medical costs, and the rare event of toxicity-induced death added $13 7 
82.32,33,44 The cost of severe TB requiring hospitalization was roughly 10 times that of 
outpatient TB treatment ($28 692 vs $29 00).32,33,44
Quality of life with LTBI and during LTBI therapy was 1.0. Quality of life with treatment-
related toxic effects was 0.75 during the month with toxic effects and 0.83 with active 
tuberculosis.38,39
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Statistical Analysis
The analysis assumed a health care sector perspective and lifetime horizon with a 3% annual 
discount to costs and benefits.45 We assumed a commonly cited willingness-to-pay threshold 
of $100 000 per quality-adjusted life-year (QALY) gained.46
We conducted deterministic sensitivity analyses, systematically altering model parameters to 
observe their effect on conclusions. Parameters of interest included test characteristics, LTBI 
prevalence, age of cohort (which relates to remaining life expectancy and cumulative TB 
risk), and quality-of-life estimates. Second-order Monte Carlo simulation was used to 
conduct 10 000 probabilistic sensitivity analyses, and LTBI prevalence, test characteristics, 
and the rate of reactivation TB were incorporated. We sampled TST and IGRA test 
characteristics from joint distributions; both prevalence of LTBI and baseline rate of 
reactivation were sampled from uniform random distributions.
Results
Across all non-US born risk populations studied, testing and treatment for LTBI prevented 
TB cases, contributed to gains in QALYs, and increased cost (Table 2). No testing resulted in 
the worst health outcomes at the least cost. The confirm positive strategy provided greater 
health outcomes than no testing and was the next strategy to be least costly. Although TST 
provided better health outcomes than confirm positive, it did so at a greater cost per QALY 
than IGRA; therefore, TST was excluded from ICER calculations through the principle of 
extended dominance. IGRA provided greater health outcomes than the confirm positive 
strategy. The confirm negative strategy delivered the best health outcomes. Since the choice 
of strategy depends on payer willingness to pay by population, we present results for each 
risk population below (Figure 1).
Non-US Born Patients With No Comorbidities Cohort
Among non-US born patients with no comorbidities, IGRA prevented 50% of lifetime TB 
reactivation compared with no testing (0.30% vs 0.60% in the total cohort), had an NNT of 
332, and was associated with an ICER of $83 000/QALY. Confirm negative prevented 13% 
more TB reactivation cases than IGRA, had an NNT of 294, and was associated with an 
ICER of $147 000/QALY.
Non-US Born Patients With Diabetes Cohort
Among non-US born patients with diabetes, confirm positive prevented 28% of lifetime TB 
reactivation compared with no testing (0.36% vs 0.50% in the total cohort), had an NNT of 
749, and was associated with an ICER of $53 000/QALY. IGRA prevented 50% of lifetime 
TB reactivation cases, had an NNT of 409, and was associated with an ICER of $120 000/
QALY. Confirm negative prevented 56% of lifetime TB reactivation cases, was associated 
with the lowest NNT of 362, and had an ICER of $230 0 00/QALY.
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Non-US Born Patients With HIV Cohort
Among non-US born patients with HIV, confirm negative prevented 55% of lifetime TB 
reactivation (0.72% vs 1.59%), had a relatively low NNT of 114, and was associated with an 
ICER of $63 000/QALY.
Non-US Born Patients With ESRD Cohort
For the non-US born patients with ESRD population, competing risks of death greatly 
limited remaining life expectancy and therefore also reduced the lifetime risk of TB 
reactivation. Testing for LTBI improved QALYs, but ICERs for all strategies were over $2 
million/QALY gained.
Sensitivity Analysis
We varied the inputs to the model to test whether our conclusions were robust under 
different circumstances and whether any general patterns could be discerned to help inform 
the choice of testing strategy. In general, the base case conclusions were robust to changes in 
core model parameters.
LTBI Prevalence
In populations with high LTBI prevalence, the confirm negative approach is most cost-
effective (Figure 2). For example, confirm negative was the preferred strategy for non-US 
born patients with no comorbidities when prevalence was greater than 23% (base case, 
15.9%) and it was preferred for non-US born patients with diabetes when the prevalence of 
LTBI was greater than 34%. Among the non-US born patients with ESRD population, no 
feasible LTBI prevalence resulted in testing being cost-effective.
At no plausible LTBI prevalence among non-US born persons was the no testing strategy 
preferred for risk populations other than ESRD. Among the non-US born patients with no 
comorbidities cohort, when prevalence is between 2.5% and 12.5%, confirm positive is the 
preferred option (ICER, $38 000/QALY); if the prevalence is below 2.5%, then no testing is 
preferred. Similarly, among the non-US born patients with diabetes cohort, confirm positive 
had an ICER of less than $100 000/QALY unless prevalence is less than 4.5%, at which 
point no testing is preferred. Among the non-US born patients with HIV cohort, IGRA 
remained cost-effective even at a prevalence of less than 1%.
TST Specificity
With modest improvement in specificity, TST became a cost-effective strategy. For example, 
when TST specificity among the non-US born patients with no comorbidities cohort was 
greater than 92.5% (base case, 88.6%), TST became the preferred strategy, and the ICER for 
IGRA compared with TST was just over the willingness-to-pay threshold ($103 000/QALY). 
However, decreases in TST specificity resulted in IGRA becoming the preferred choice. For 
example, in the non-US born patients with diabetes cohort with TST specificity less than 
64%, IGRA became the preferred strategy, with an ICER compared with confirm positive of 
$100 000/QALY.
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TST Return Rate
Only substantial improvements in rates of follow-up made TST cost-effective (Figure 2). For 
example, among the non-US born patients with no comorbidities cohort when more than 
91.5% of individuals returned (base case, 82%), TST became the preferred strategy (ICER 
compared with confirm positive, $86 000/QALY). When return for TST in the non-US born 
patients with diabetes cohort was less than 58%, IGRA was the cost-effective strategy.
Age
Some form of testing and treatment was cost-effective regardless of age. In younger persons, 
the cumulative lifetime risk of reactivation is higher than in older persons; therefore, more 
sensitive testing algorithms became economically attractive. For example, when we assumed 
the non-US born patients with diabetes population was younger (35 years), IGRA became 
the preferred strategy (ICER, $59 000/QALY compared with confirm positive). Likewise, a 
further reduction in age among non-US born patients with diabetes to 30 years resulted in 
confirm negative being the preferred strategy (ICER, $100 000/QALY).
Quality of Life With LTBI and Post-TB
If living with LTBI carried any associated disutility (0.99), then confirm negative became 
clearly preferred for all groups other than non-US born patients with ESRD. If recovering 
from TB conveyed permanent pulmonary sequelae associated with modest disutility,47 
strategies using IGRA were preferred for all groups other than non-US born patients with 
ESRD. Confirm negative was preferred when the health state utility of cured TB was less 
than 0.97 among non-US born patients with no comorbidities and when it was less than 0.87 
for the non-US born patients with diabetes cohort.
Probabilistic Sensitivity Analysis
Among the non-US born patients with no comorbidities cohort, some form of LTBI testing 
was cost-effective in more than 90% of simulations (Figure 3). IGRA was the preferred 
strategy in 29% of simulations, confirm negative was preferred for 20%, confirm positive 
was preferred in 17% of simulations, and TST was the preferred strategy in 25% of 
simulations.
For the non-US born patients with diabetes cohort, some form of testing was cost-effective 
in all simulations. Confirm positive was the preferred strategy in 39.5% of the simulations, 
and IGRA was preferred in 21.8%; TST was the preferred strategy in 38.7% of the 
simulations.
For the non-US born patients with HIV cohort, confirm negative was the preferred strategy 
in 63% of simulations, IGRA was preferred 31% of the time, and TST was preferred in 6% 
of the cases. Confirm positive was preferred in fewer than 1% of the simulations. Finally, for 
the non-US born patients with ESRD cohort, no testing was the preferred strategy in 100% 
of the simulations.
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Discussion
We used simulation modeling to project the long-term outcomes and cost-effectiveness of 
strategies for testing and treating LTBI among non-US born individuals with and without 
common comorbidities. First, we found that testing for LTBI in non-US born individuals 
followed by 3 months of self-administered rifapentine and isoniazid therapy prevents 
reactivation TB, improves health outcomes, and is cost-effective compared with no LTBI 
testing or treatment. The exception is for non-US born patients with ESRD, where 
competing risks of death substantially reduce the benefits of treatment such that no testing is 
cost-effective.
Second, we demonstrated that TST alone-one common approach to testing-is likely not the 
best use of limited TB control resources among non-US born persons. In over 60% of the 
simulations for the non-US born patients with no comorbidities and non-US born patients 
with diabetes and in 94% of simulations for the non-US born patients with HIV cohort, 
some sequence of testing with IGRA was preferred. Both lower specificity and loss to 
follow-up associated with TST reduce its cost-effectiveness. If only testing cost is 
considered in the design of TB control strategies, TST might be selected despite the fact that 
IGRA provides better outcomes per dollar spent. Tuberculosis control programs can use 
these results to identify effective candidate strategies.
Third, we found that, among non-US born patients with HIV in whom both the prevalence of 
LTBI and the risk of re-activation are high, testing algorithms should maximize test 
sensitivity to approach treatment for all cases of LTBI. Among non-US born patients with 
HIV, the confirm negative algorithm suggested in current Centers for Disease Control and 
Prevention guidance is economically attractive, assuming a $100 000 willingness-to-pay 
threshold.13
Among the non-US born patients with no comorbidities and non-US born patients with 
diabetes, the choice of how to use IGRA–either alone or in combination with TST to 
maximize either specificity or sensitivity–is more complex. Our probabilistic sensitivity 
analyses results highlight the level of uncertainty in this decision. Some sequence of IGRA 
testing was preferred in the majority of simulations, but each algorithm that used IGRA had 
a similar probability of being preferred at a willingness-to-pay threshold of less than $100 
000/QALY. The single-variable sensitivity analyses, however, shed some light on the 
dynamics behind this uncertainty and should help decision makers to navigate this obstacle. 
The cost-effectiveness of TST is highly dependent on its specificity and return rate. For non-
US born patients with no comorbidities, IGRA provides a 1-step testing algorithm that has 
good health outcomes and whose ICER is below a $100 000 willingness-to-pay threshold; 
for non-US born patients with diabetes, the ICER for IGRA was $120 000/QALY, just over a 
$100 000 willingness-to-pay threshold. Although a strict interpretation recommends confirm 
positive as the preferred strategy for the non-US born patients with diabetes population, the 
sensitivity of this conclusion to key parameters, such as LTBI prevalence and TST return, 
suggests that it is not definite. When policymakers consider additional factors that were not 
explicitly modeled, such as patient convenience and the desire to publish simple, effective 
guidance applicable to all non-US born individuals, evidence mounts to recommend 1-step 
Tasillo et al. Page 8
JAMA Intern Med. Author manuscript; available in PMC 2018 June 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
IGRA testing for both the non-US born patients with no comorbidities and non-US born 
patients with diabetes groups. With additional available resources or a prevalence of LTBI 
approaching the high end of estimates, it is likely reasonable to follow-up a negative IGRA 
with a TST for added sensitivity.
Limitations
It is notable that LTBI testing and treatment among non-US born patients with ESRD was 
not cost-effective. Among patients undergoing dialysis, competing risks of death limit life 
expectancy, which reduces the remaining years at risk for developing TB and limits the 
benefit of preventing TB. One limitation of our study is that the model only considered 1 
generation of TB transmission. While we did not find that LTBI treatment was likely to be 
cost-effective among non–US born patients with ESRD, another rationale for TB testing in 
dialysis centers might be to prevent TB outbreaks in hospitals and ensure infection control.
There are additional limitations to this study. The prevalence of LTBI and the test 
characteristics of TST and IGRA are impossible to directly observe and difficult to estimate 
without a reference standard for LTBI diagnosis. One strength of our analysis is the 
synthesis of multiple data sources to inform TST and IGRA sensitivity and specificity. We 
used second-order Monte Carlo simulation to test the robustness of base-case conclusions 
and transparently demonstrate the quantitative effect of such uncertainty on our conclusions. 
Similarly, the rate of TB reactivation over decades of remaining life is uncertain. We 
modeled decreasing reactivation over time, consistent with observational data, and also 
explored the impact of reactivation rates in probabilistic sensitivity analyses. In addition, if 
we were to implement a societal framework through which to consider costs and benefits, 
the additional costs to patients due to the need to return for a TST reading may further 
reduce the appeal of strategies using TST.
Conclusions
This study highlights the need for observational research about the relative performance of 
tests for LTBI as well as the necessity of less costly, better-performing tests. A single test 
with improved characteristics and a lower cost than that of IGRA could reduce investment 
needed in terms of patient and provider time and cost and make universal testing for non–US 
born patients even more attractive.
Targeted testing and treatment for LTBI remains a corner-stone of the US TB elimination 
plan. We found that LTBI testing and treatment among non–US born persons with 
comorbidities, including diabetes and HIV, prevents cases of TB, improves quality-adjusted 
life expectancy, and is cost-effective. Targeted testing and treatment for LTBI among non–
US born people with and without common comorbidities, using IGRAs and 3 months of 
self-administered rifapentine and isoniazid, are effective and provide good value for the 
resources invested.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Key Points
Question
What is the optimal approach to testing for latent tuberculosis infection among residents 
born outside the United States with and without HIV, diabetes, and end-stage renal 
disease?
Findings
This Markov cohort simulation model study found that some type of latent tuberculosis 
infection testing and treatment with 3 months of rifapentine and isoniazid likely was 
associated with an incremental cost-effectiveness ratio below $100 000 per quality-
adjusted life-year except for patients with end-stage renal disease. Strategies using 
interferon gamma release assay were likely preferred; tuberculin skin testing alone is 
likely dominated.
Meaning
It is cost-effective to test and treat non-US born residents for latent tuberculosis infection, 
although the choice of test depends on patient comorbidities and resources available.
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Figure 1. Primary Cost-effectiveness Results in Non–US Born Patients
A, The best-performing strategy with an incremental cost-effectiveness ratio (ICER) below 
$100 000/quality-adjusted life-year (QALY). B, Strategies that are likely to improve health 
outcomes compared with the strategy indicated in panel A but are associated with ICERs 
above $100 000/QALY. ICERs are calculated against the next-best alternative strategy and 
are shown in 2015 US dollars per QALY gained. IGRA indicates interferon gamma release 
assay.
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Figure 2. Effect of Tuberculin Skin Test (TST) Return and Latent Tuberculosis Infection (LTBI) 
Prevalence on Cost-effectiveness Conclusions in Non–US Born Patients
A, A 1-way sensitivity analysis demonstrating the effect of TST return on the cost-
effectiveness conclusions for interferon gamma release assay (IGRA) testing and IGRA plus 
TST for sensitivity testing. B, An illustration of the effect of LTBI prevalence on cost-
effectiveness conclusions for IGRA testing and confirm negative testing. In the confirm 
negative strategy, patients first underwent IGRA. If that test was positive, LTBI was 
diagnosed. If that test was negative, then the patient underwent TST. LTBI was ruled out 
only if both tests were negative. For each risk population, there is a unique LTBI prevalence 
above which IGRA requires more investment to gain the same amount of quality-adjusted 
life-years (QALYs) than confirm negative. Above this point, IGRA is excluded from 
consideration as a viable strategy and thus is not represented in the figure. The apparent 
discontinuity at high prevalence (>90% non–US born patients with diabetes, >80% non–US 
born individuals with no comorbidities) emerges when confirm negative is not only a cost-
effective strategy but becomes more favorable than other, less costly strategies. Incremental 
cost-effectiveness ratios (ICERs) are calculated against the next-best alternative strategy and 
are shown in 2015 US dollars per QALY gained. End-stage renal disease was excluded from 
this figure because it is cost-ineffective.
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Figure 3. Cost-effectiveness Acceptability Curves Representing the Proportion of Simulations for 
Which Each Strategy Was Preferred at a Given Willingness-to-Pay Threshold
Probabilistic sensitivity analysis was performed on reactivation rate, LTBI prevalence, and 
test characteristics in non–US born persons with no comorbidities (A), those with HIV (B), 
individuals with diabetes (C), and those with end-stage renal disease (D). IGRA indicates 
interferon gamma release assay; TST, tuberculin skin test.
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Table 1
Cohort Description and Select Model Input Parameters for a Cost-effectiveness Analysis of Testing and 
Treating LTBI Among Non-US Born Residents
Variable Base-Case Value Range Evaluated
Proportion male21          0.490          0.40–0.60
LTBI prevalence22          0.159          0.0–1.0
Age at baseline, y
NC2        35        30–70
HIV2        35        30–70
Diabetes2        57        30–70
ESRD2        58        30–70
Life expectancy without LTBI
 NC23        80        70–90
 HIV18,23,24        69        60–80
 Diabetes17,23        75        70–80
 ESRD19        65        60–70
Cascade of testing and treatment
 Return for TST read25          0.820          0.0–1.0
 Diagnosed who initiate treatment26          0.900          0.5–1.0
 Treatment completion7          0.783          0.5–1.0
 Hepatotoxicity4,7          0.005          0.0–0.01
 Mortality with hepatotoxicity27          0.001          0.0–0.002
Lifetime risk of TB reactivation, untreated infection
 NC22          0.038          0.01–0.1
 HIV28          0.100          0.05–0.2
 Diabetes22,29          0.031          0.01–0.1
 ESRD22,29          0.012          0.005–0.05
Reduction in reactivation probability after complete therapy2,4          0.900          0.5–1.0
Proportion with severe TB requiring hospitalization30          0.503          0.25–0.75
Mortality with TB1          0.050          0.025–0.075
Secondary cases31          0.250          0.1–1.0
Costs, $
 TST32          7.870          5–15
 IGRA33        84.350        50–100
 Complete course of therapy32–34      582      300–1000
 Treatment for hepatotoxicity32–34      323      250–500
 Treatment for nonsevere active TB32–34    2900    1500–4500
 Treatment for severe active TB32–34 28 692 10 000–40 000
JAMA Intern Med. Author manuscript; available in PMC 2018 June 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Tasillo et al. Page 18
Variable Base-Case Value Range Evaluated
Monthly health care costs, $
 NC35      106–1374        53–2061
 HIV24    2061    1030–3091
 Diabetes36      788–2056      394–3084
 ESRD37    3900–5168    1750–7752
Utility measures
 LTBIa          1          0.99–1.0
 Hepatotoxicity38          0.750          0.6–1.0
 Active TB39          0.830          0.75–1.0
 Post-TB quality of lifea          1          0.87–1.0
TST sensitivity (%)b in non–US born patients
 With no comorbidities        71          0.5–1.0
 With HIV        67          0.5–1.0
 With diabetes        67          0.5–1.0
 With ESRD        67          0.5–1.0
IGRA sensitivity (%)b in non–US born patients
 With no comorbidities        79          0.5–1.0
 With HIV        77          0.5–1.0
 With diabetes        78          0.5–1.0
 With ESRD        78          0.5–1.0
TST specificity (%)b in non–US born patients
 With no comorbidities        89          0.5–1.0
 With HIV        87          0.5–1.0
 With diabetes        87          0.5–1.0
 With ESRD        87          0.5–1.0
IGRA specificity (%)b in non–US born patients
 With no comorbidities        99          0.5–1.0
 With HIV        99          0.5–1.0
 With diabetes        98          0.5–1.0
 With ESRD        98          0.5–1.0
Abbreviations: D, diabetes; ESRD, end-stage renal disease; IGRA, interferon gamma release assay; LTBI, latent tuberculosis infection; NC, no 
comorbidities; TB, tuberculosis; TST, tuberculin skin test.
a
Model assumption.
b
eAppendix in the Supplement.
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